Bristol Myers Squibb Company
NEWS
bluebird bio has completed the spin-off of its oncology programs into the new business entity, 2seventy bio, Inc, which will begin trading on the Nasdaq this morning under the ticker symbol “TSVT.”
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
Monday was a big day for LianBio, as the Shanghai-based company launched on the Nasdaq with an impressive $325 million initial public offering (IPO).
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
Yet another busy week for clinical trial news. Here’s a look.
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
Bristol Myers Squibb is reportedly courting Canada’s Aurinia Pharmaceuticals to strike a buyout deal.
The designation is based on data from two Phase I trials, which showed the drug to be safe, demonstrating early efficacy.
Transition Bio named Gregory Miller as chief executive officer, Prof. Tuomas Knowles as chief technology officer and Martin Kulander as chief operating officer, among several others.
JOBS
IN THE PRESS